You are here
P&T July 2015
Years of complaints about poor access to information on “compassionate use” of experimental drugs and a lack of transparency in clinical trials are driving reform efforts by the National Library of Medicine, the Food and Drug Administration, and Congress.
Many studies have evaluated the role of vasopressors and inotropes in the management of septic shock. This review assesses evidence for the use of specific vasopressors, adjunctive vasopressor therapy, and inotropic agents for myocardial dysfunction.
Sodium-glucose linked transporter 2 inhibitors limit the reabsorption of glucose from glomerular filtrate in the kidneys, reducing blood glucose levels in patients with type- 2 diabetes. This article is meant to evaluate this class of medications for clinicians.
We review key sessions on pharmacological treatment, including four on irritable bowel syndrome and others on pancreatitis and Helicobacter pylori infection.
Life-threatening sepsis presents with varying symptoms due to the wide range of pathogens that cause it, and sepsis-specific treatment options for patients are sparse.
Safety strategies for avoiding tragedies with Lugol’s solution
FDA may step up enforcement for homeopathic products.
FDA approvals, drug indications, and updates
Deoxycholic acid (Kybella) for submental fat; codeine polistirex/chlorpheniramine polistirex extended-release (Tuzistra XR) for coughs, allergies, and colds; ramucirumab (Cyramza) for colorectal cancer; and fluticasone furoate/vilanterol (Breo Ellipta) for asthma
Ramucirumab (Cyramza): A breakthrough treatment for gastric cancer